Literature DB >> 27035165

Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.

Kelsey L Watson1, Ghadah A Al Sannaa2, Christine M Kivlin1,3, Davis R Ingram2, Sharon M Landers1, Christina L Roland1, Janice N Cormier1, Kelly K Hunt1, Barry W Feig1, B Ashleigh Guadagnolo4, Andrew J Bishop4, Wei-Lien Wang2, John M Slopis5, Ian E McCutcheon6, Alexandar J Lazar3, Keila E Torres1.   

Abstract

OBJECTIVE Malignant peripheral nerve sheath tumors (MPNSTs) are an aggressive group of soft tissue sarcomas that can arise sporadically, in the context of neurofibromatosis Type 1 (NF1) or at a site of prior irradiation. Large series profiling the features and outcomes of sporadic, NF1-associated, and radiation-associated MPNSTs are limited. The goal of this study was to elucidate differences between MPNST etiologies in a large single-institution retrospective study. METHODS Patients (n = 317) were identified through the tumor registry of The University of Texas MD Anderson Cancer Center. Clinicopathological features were retrospectively collected. Features were compared among MPNST subtypes for patients who had sufficient clinical history (n = 289), and clinicopathological features were used to identify adverse predictors of recurrence and survival outcomes. RESULTS Five-year local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), and disease-specific survival (DSS) estimates were 56.6%, 49.6%, and 53.6%, respectively, for the high-grade MPNST cohort. Five-year DSS was lower in NF1-associated and radiation-associated MPNST than in sporadic MPNST (52%, 47%, and 67%, respectively, p = 0.140). Patients with radiation-associated MPNST had worse 5-year LRFS than those with the sporadic and NF1-associated subtypes (RT-associated vs sporadic, p = 0.010; RT-associated vs NF1-associated, p = 0.232). Truncally located tumors, positive surgical margins, local recurrence, and metastasis were predictors of adverse DSS in multivariate analysis. CONCLUSIONS Radiation-associated MPNSTs are associated with poorer local recurrence-free and disease-specific survival than sporadic and NF1-associated tumors. NF1-associated MPNSTs may have worse survival outcomes owing to large tumor size, compromising truncal location, and lower rate of negative resection margins compared with sporadic tumors.

Entities:  

Keywords:  DRFS = distant recurrence-free survival; DSS = disease-specific survival; HR = hazard ratio; LRFS = local recurrence-free survival; MPNST; MPNST = malignant peripheral nerve sheath tumor; NF1 = neurofibromatosis Type 1; malignant peripheral nerve sheath tumor; neurofibromatosis Type 1; radiation-induced sarcoma

Mesh:

Year:  2016        PMID: 27035165      PMCID: PMC5045773          DOI: 10.3171/2015.12.JNS152443

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  23 in total

1.  Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.

Authors:  Jennifer LaFemina; Li-Xuan Qin; Nicole H Moraco; Cristina R Antonescu; Ryan C Fields; Aimee M Crago; Murray F Brennan; Samuel Singer
Journal:  Ann Surg Oncol       Date:  2012-08-10       Impact factor: 5.344

2.  Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group.

Authors:  F Mertens; P Dal Cin; I De Wever; C D Fletcher; N Mandahl; F Mitelman; J Rosai; A Rydholm; R Sciot; G Tallini; H van Den Berghe; R Vanni; H Willén
Journal:  J Pathol       Date:  2000-01       Impact factor: 7.996

3.  Malignant peripheral nerve sheath tumor (MPNST) arising in diffuse-type neurofibroma: clinicopathologic characterization in a series of 9 cases.

Authors:  Inga-Marie Schaefer; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2015-09       Impact factor: 6.394

4.  Lessons learned from the study of 10,000 patients with soft tissue sarcoma.

Authors:  Murray F Brennan; Cristina R Antonescu; Nicole Moraco; Samuel Singer
Journal:  Ann Surg       Date:  2014-09       Impact factor: 12.969

5.  Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor.

Authors:  Q Fan; J Yang; G Wang
Journal:  Clin Transl Oncol       Date:  2013-06-08       Impact factor: 3.405

Review 6.  Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations.

Authors:  Stephen R Grobmyer; John D Reith; Amir Shahlaee; Charles H Bush; Steven N Hochwald
Journal:  J Surg Oncol       Date:  2008-03-15       Impact factor: 3.454

7.  Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

Authors:  Gunnar Johansson; Yonatan Y Mahller; Margaret H Collins; Mi-Ok Kim; Takahiro Nobukuni; John Perentesis; Timothy P Cripe; Heidi A Lane; Sara C Kozma; George Thomas; Nancy Ratner
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

8.  Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.

Authors:  Changye Zou; Kerrington D Smith; Jun Liu; Guy Lahat; Sarah Myers; Wei-Lien Wang; Wei Zhang; Ian E McCutcheon; John M Slopis; Alexander J Lazar; Raphael E Pollock; Dina Lev
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

Review 9.  Malignant peripheral nerve sheath tumors.

Authors:  Mohamad Farid; Elizabeth G Demicco; Roberto Garcia; Linda Ahn; Pamela R Merola; Angela Cioffi; Robert G Maki
Journal:  Oncologist       Date:  2014-01-27

Review 10.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

Authors:  Matthias Kolberg; Maren Høland; Trude H Agesen; Helge R Brekke; Knut Liestøl; Kirsten S Hall; Fredrik Mertens; Piero Picci; Sigbjørn Smeland; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2012-11-15       Impact factor: 12.300

View more
  30 in total

1.  Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.

Authors:  Christian Philipp Reinert; Martin Ulrich Schuhmann; Benjamin Bender; Isabel Gugel; Christian la Fougère; Jürgen Schäfer; Sergios Gatidis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-08       Impact factor: 9.236

Review 2.  Cancer of the Peripheral Nerve in Neurofibromatosis Type 1.

Authors:  Verena Staedtke; Ren-Yuan Bai; Jaishri O'Neill Blakeley
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 3.  The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Authors:  Souvik Karmakar; Karlyne M Reilly
Journal:  CNS Oncol       Date:  2016-12-21

Review 4.  Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.

Authors:  Justin Korfhage; David B Lombard
Journal:  Mol Cancer Res       Date:  2019-04-25       Impact factor: 5.852

Review 5.  Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.

Authors:  Markku M Miettinen; Cristina R Antonescu; Christopher D M Fletcher; Aerang Kim; Alexander J Lazar; Martha M Quezado; Karlyne M Reilly; Anat Stemmer-Rachamimov; Douglas R Stewart; David Viskochil; Brigitte Widemann; Arie Perry
Journal:  Hum Pathol       Date:  2017-05-24       Impact factor: 3.466

6.  NF1+/- Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response.

Authors:  Rebecca D Dodd; Chang-Lung Lee; Tess Overton; Wesley Huang; William C Eward; Lixia Luo; Yan Ma; Davis R Ingram; Keila E Torres; Diana M Cardona; Alexander J Lazar; David G Kirsch
Journal:  Cancer Res       Date:  2017-06-23       Impact factor: 12.701

7.  Surgical Management of Symptomatic Lumbar, Sacral, and Lumbosacral Plexus Tumors: a Peripheral Nerve Unit Experience.

Authors:  Fernando Guedes; Gabriel Elias Sanches; Rosana Siqueira Brown; Rodrigo Salvador Vivas Cardoso; Ana Caroline Siquara-de-Sousa; Agostinho Ascenção; Antônio Carlos Iglesias
Journal:  Acta Neurochir (Wien)       Date:  2021-03-10       Impact factor: 2.216

8.  Incidence of second malignancies in individuals diagnosed with malignant peripheral nerve sheath tumors.

Authors:  Lindsay A Williams; Christopher L Moertel; Michaela Richardson; Erin L Marcotte
Journal:  J Neurooncol       Date:  2020-04-01       Impact factor: 4.130

9.  Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Douglas R Stewart; Bruce R Korf; Katherine L Nathanson; David A Stevenson; Kaleb Yohay
Journal:  Genet Med       Date:  2018-04-26       Impact factor: 8.822

10.  Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.

Authors:  Veena Kochat; Ayush T Raman; Sharon M Landers; Ming Tang; Jonathan Schulz; Christopher Terranova; Jace P Landry; Angela D Bhalla; Hannah C Beird; Chia-Chin Wu; Yingda Jiang; Xizeng Mao; Rossana Lazcano; Swati Gite; Davis R Ingram; Min Yi; Jianhua Zhang; Emily Z Keung; Christopher P Scally; Christina L Roland; Kelly K Hunt; Barry W Feig; P Andrew Futreal; Patrick Hwu; Wei-Lien Wang; Alexander J Lazar; John M Slopis; Heather Wilson-Robles; Dominique J Wiener; Ian E McCutcheon; Brandan Wustefeld-Janssens; Kunal Rai; Keila E Torres
Journal:  Acta Neuropathol       Date:  2021-07-20       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.